Description

Sacubitril is a potent and selective neprilysin (NEP) inhibitor, a key active pharmaceutical ingredient (API) in modern cardiovascular therapy. Its primary commercial value lies in its critical role in the combination drug sacubitril/valsartan, which is a first-in-class angiotensin receptor-neprilysin inhibitor (ARNI) for the treatment of heart failure. This compound is essential for pharmaceutical manufacturers and R&D facilities focused on developing and producing innovative cardiovascular medications. Sacubitril CAS NO 565453-99-8 represents a high-value intermediate requiring stringent quality control for optimal therapeutic efficacy.

Application

• Active Pharmaceutical Ingredient (API): Primary use as the neprilysin-inhibiting component in the blockbuster combination drug sacubitril/valsartan for chronic heart failure.
• Pharmaceutical R&D: Serves as a critical reference standard and starting material for research into novel neprilysin inhibitors and next-generation ARNI therapies.
• Generic Drug Manufacturing: A vital raw material for companies developing and producing generic versions of sacubitril/valsartan upon patent expiry.
• Clinical Trial Material: Supplied under GMP conditions for use in Phase I-IV clinical studies investigating heart failure and related cardiovascular conditions.
• Biochemical Research: Used in enzymatic studies to investigate the role of neprilysin in peptide hormone regulation, including natriuretic peptides.

Basic Information

Item	Detail
Product Name	Sacubitril
CAS No.	565453-99-8
Molecular Formula	C24H29NO5
Molecular Weight	411.49 g/mol
Synonyms	AHU-377; (2R,4S)-5-Biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester; N-[(2S,4R)-1-(1,1'-Biphenyl]-4-ylmethyl)-5-ethoxy-4-methyl-5-oxopentan-2-yl]-4-(methylsulfanyl)butanamide; LCZ696 Sacubitril; Entresto component; Neprilysin inhibitor AHU377
EINECS	Contact for details

Quality Control

Our Sacubitril is manufactured under strict quality management systems, targeting standards suitable for pharmaceutical applications. Each batch is subjected to comprehensive analytical testing, including identity confirmation, purity assay, and impurity profiling via advanced techniques like HPLC and chiral chromatography. A Certificate of Analysis (COA) is provided with each shipment, detailing all critical quality attributes. We support compliance with ICH Q7 guidelines and can supply material suitable for use in GMP-regulated environments.

Storage

Preserve in a tightly closed container, protected from light. Store in a cool, dry place at controlled room temperature (15-25°C). Keep the container tightly sealed in a dry environment to protect this light-sensitive compound from degradation.

Specification

Item	Specification
Appearance	White to off-white powder
Identification (IR)	Conforms to reference spectrum
Identification (HPLC)	Retention time matches reference standard
Assay (HPLC)	≥98.5%
Chiral Purity (HPLC)	≥99.0%
Related Substances (HPLC)	Total impurities ≤1.0% Any single impurity ≤0.5%
Residual Solvents (GC)	Complies with ICH Q3C
Heavy Metals	≤20 ppm
Loss on Drying	≤0.5%

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.